Skip to main content
Top
Published in: Pathology & Oncology Research 2/2011

01-06-2011 | Research

Prognostic Significance of p53 Protein Expression in Early Gastric Cancer

Authors: Andrea Rodrigues Gonçalves, Antonio Jose Vasconcellos Carneiro, Ivanir Martins, Paulo Antonio Silvestre de Faria, Maria Aparecida Ferreira, Eduardo Linhares Riello de Mello, Homero Soares Fogaça, Celeste Carvalho Siqueira Elia, Heitor Siffert Pereira de Souza

Published in: Pathology & Oncology Research | Issue 2/2011

Login to get access

Abstract

Mutations of the p53 tumor suppressor gene have been associated with abnormalities in cell cycle regulation, DNA repair and synthesis, apoptosis, and it has been implicated in the prognosis of advanced gastric cancer. The aim of this study was to evaluate the occurrence of p53 gene mutation and its possible prognostic implications in early gastric cancer. In a retrospective study, we studied 80 patients with early gastric cancer treated surgically between 1982 and 2001. Mutation of p53 gene was investigated in surgical gastric specimens by immunohistochemistry, and results were analyzed in relation to gender, age, macroscopic appearance, size and location of tumor, presence of lymph nodes, Lauren’s histological type, degree of differentiation, and the 5-year survival. The expression of p53 was more frequent among the intestinal type (p = 0.003), the differentiated (p = 0.007), and the macroscopically elevated tumors (p = 0.038). Nevertheless, the isolated expression of p53 was not associated with the 5-year survival, or with the frequency of lymph node involvement. The degree of differentiation was detected as an independent factor related to the outcome of patients (0.044). Significantly shorter survival time was found in p53-negative compared with p53-positive patients, when considering the degree of differentiation of tumors, as assessed by Cox regression analysis (0.049). The association of p53 with the intestinal type, the degree of differentiation and morphological characteristics, may reflect the involvement of chronic inflammatory process underlying early gastric cancer. In this population sample, the expression of p53 alone has no prognostic value for early gastric cancer. However, the significant difference in p53 expression between subgroups of degree of differentiation of tumors can influence post-operative outcome of patients and may be related to possible distinct etiopathogenic subtypes.
Literature
1.
go back to reference Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654PubMedCrossRef Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654PubMedCrossRef
2.
go back to reference Boussioutas A, Taupin D (2001) Towards a molecular approach to gastric cancer management. Intern Med J 31:296–303PubMedCrossRef Boussioutas A, Taupin D (2001) Towards a molecular approach to gastric cancer management. Intern Med J 31:296–303PubMedCrossRef
4.
go back to reference Field K, Michael M, Leong T (2008) Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 68:299–317PubMedCrossRef Field K, Michael M, Leong T (2008) Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 68:299–317PubMedCrossRef
5.
go back to reference Kaibara N, Sumi K, Yonekawa M, Ohta M, Makino M, Kimura O, Nishidoi H, Koga S (1990) Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am J Surg 159:218–221PubMedCrossRef Kaibara N, Sumi K, Yonekawa M, Ohta M, Makino M, Kimura O, Nishidoi H, Koga S (1990) Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am J Surg 159:218–221PubMedCrossRef
6.
go back to reference Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K (2000) Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 128:408–416PubMedCrossRef Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K (2000) Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 128:408–416PubMedCrossRef
7.
go back to reference Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20:633–649PubMedCrossRef Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20:633–649PubMedCrossRef
8.
go back to reference Anderson C, Nijagal A, Kim J (2006) Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 10:345–352PubMed Anderson C, Nijagal A, Kim J (2006) Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 10:345–352PubMed
9.
go back to reference Smith MG, Hold GL, Tahara E, El-Omar EM (2006) Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12:2979–2990PubMed Smith MG, Hold GL, Tahara E, El-Omar EM (2006) Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12:2979–2990PubMed
11.
go back to reference Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed
12.
go back to reference Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al (1998) IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res 26:205–213PubMedCrossRef Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al (1998) IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res 26:205–213PubMedCrossRef
13.
go back to reference Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed
14.
go back to reference Hollstein M, Sidransky D, Vogelstein B, Harris C (1991) p53 mutations in human cancers. Science 253:49–53PubMedCrossRef Hollstein M, Sidransky D, Vogelstein B, Harris C (1991) p53 mutations in human cancers. Science 253:49–53PubMedCrossRef
15.
16.
go back to reference Starzynska T, Bromley M, Ghosh A, Stern PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558–562PubMedCrossRef Starzynska T, Bromley M, Ghosh A, Stern PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558–562PubMedCrossRef
17.
go back to reference Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589–593PubMedCrossRef Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589–593PubMedCrossRef
18.
go back to reference Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946PubMedCrossRef Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946PubMedCrossRef
19.
go back to reference Motojima K, Furui J, Kohara N, Ito T, Kanematsu T (1994) Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116:890–895PubMed Motojima K, Furui J, Kohara N, Ito T, Kanematsu T (1994) Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116:890–895PubMed
20.
go back to reference Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–726PubMedCrossRef Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–726PubMedCrossRef
21.
go back to reference Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstädter F, Hartmann A (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 56:286–92PubMedCrossRef Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstädter F, Hartmann A (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 56:286–92PubMedCrossRef
22.
go back to reference Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T (1999) Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57:131–137PubMedCrossRef Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T (1999) Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57:131–137PubMedCrossRef
23.
go back to reference Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed
24.
go back to reference Montesano R, Hollstein M, Hainaut P (1996) Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69:225–235PubMedCrossRef Montesano R, Hollstein M, Hainaut P (1996) Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69:225–235PubMedCrossRef
25.
go back to reference Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240PubMedCrossRef Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240PubMedCrossRef
27.
go back to reference Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumorsuppressor gene in clinical oncology. J Clin Oncol 13:1009–1022PubMed Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumorsuppressor gene in clinical oncology. J Clin Oncol 13:1009–1022PubMed
28.
go back to reference Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E (1992) p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 119:67–70PubMedCrossRef Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E (1992) p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 119:67–70PubMedCrossRef
29.
go back to reference Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S (1993) p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54:759–764PubMedCrossRef Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S (1993) p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54:759–764PubMedCrossRef
30.
go back to reference Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273:1–4PubMedCrossRef Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273:1–4PubMedCrossRef
31.
go back to reference Hall PA, Lane DP (1994) p53 in tumor pathology: can we trust immunohistochemistry?-Revisited! J Pathol 72:1–4CrossRef Hall PA, Lane DP (1994) p53 in tumor pathology: can we trust immunohistochemistry?-Revisited! J Pathol 72:1–4CrossRef
32.
go back to reference Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602PubMed Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602PubMed
33.
34.
go back to reference Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K (1999) Prognostic value of p53 protein expression for patients with gastric cancer—a multivariate analysis. Br J Cancer 79:1255–1261PubMedCrossRef Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K (1999) Prognostic value of p53 protein expression for patients with gastric cancer—a multivariate analysis. Br J Cancer 79:1255–1261PubMedCrossRef
35.
go back to reference Ming SC (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer 1:31–50PubMedCrossRef Ming SC (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer 1:31–50PubMedCrossRef
36.
go back to reference Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ (2001) Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res 21:513–520PubMed Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ (2001) Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res 21:513–520PubMed
37.
go back to reference Tahara E, Semba S, Tahara H (1996) Molecular biological observations in gastric cancer. Semin Oncol 23:307–315PubMed Tahara E, Semba S, Tahara H (1996) Molecular biological observations in gastric cancer. Semin Oncol 23:307–315PubMed
38.
go back to reference Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT (1998) Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 78:971–973PubMedCrossRef Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT (1998) Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 78:971–973PubMedCrossRef
39.
go back to reference Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, Lin JT (2000) Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 118:1031–1038PubMedCrossRef Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, Lin JT (2000) Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 118:1031–1038PubMedCrossRef
40.
go back to reference Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735–6740PubMed Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735–6740PubMed
41.
go back to reference Kodama M, Fujioka T, Murakami K, Okimoto T, Sato R, Watanabe K, Nasu M (2005) Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol 20:941–946PubMedCrossRef Kodama M, Fujioka T, Murakami K, Okimoto T, Sato R, Watanabe K, Nasu M (2005) Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol 20:941–946PubMedCrossRef
42.
go back to reference Morgan C, Jenkins GJS, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM (2003) Detection of p53 mutations in precancerous gastric tissue. Br J Cancer 89:1314–1319PubMedCrossRef Morgan C, Jenkins GJS, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM (2003) Detection of p53 mutations in precancerous gastric tissue. Br J Cancer 89:1314–1319PubMedCrossRef
43.
go back to reference Kodama M, Murakami K, Okimoto T, Sato R, Watanabe K, Fujioka T (2007) Expression of mutant type-p53 products in H pylori-associated chronic gastritis. World J Gastroenterol 13:1541–1546PubMed Kodama M, Murakami K, Okimoto T, Sato R, Watanabe K, Fujioka T (2007) Expression of mutant type-p53 products in H pylori-associated chronic gastritis. World J Gastroenterol 13:1541–1546PubMed
44.
go back to reference Li JH, Shi XZ, Lv S, Liu M, Xu GW (2005) Effect of helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J Gastroenterol 11:4363–4366PubMed Li JH, Shi XZ, Lv S, Liu M, Xu GW (2005) Effect of helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J Gastroenterol 11:4363–4366PubMed
45.
go back to reference Maehara Y, Kakeji Y, Oda S, Baba H, Sugimachi K (2001) Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology 61:102–112PubMedCrossRef Maehara Y, Kakeji Y, Oda S, Baba H, Sugimachi K (2001) Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology 61:102–112PubMedCrossRef
46.
go back to reference Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K (2001) Growth pattern and expressions of cell cycle regulator proteins p53 and p21 WAF1/CIP1 in early gastric carcinoma. Cancer 92:1828–1835PubMedCrossRef Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K (2001) Growth pattern and expressions of cell cycle regulator proteins p53 and p21 WAF1/CIP1 in early gastric carcinoma. Cancer 92:1828–1835PubMedCrossRef
47.
go back to reference McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735–738PubMedCrossRef McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735–738PubMedCrossRef
48.
go back to reference Hamilton JP, Meltzer SJ (2006) A Review of the Genomics of Gastric Cancer. Clin Gastroenterol Hepatol 4:416–425PubMedCrossRef Hamilton JP, Meltzer SJ (2006) A Review of the Genomics of Gastric Cancer. Clin Gastroenterol Hepatol 4:416–425PubMedCrossRef
49.
go back to reference Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24–30PubMedCrossRef Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24–30PubMedCrossRef
50.
go back to reference Lu C-D, Altieri DC, Tanigawa N (1998) Expression of A Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas. Cancer Res 58:1808–1812PubMed Lu C-D, Altieri DC, Tanigawa N (1998) Expression of A Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas. Cancer Res 58:1808–1812PubMed
Metadata
Title
Prognostic Significance of p53 Protein Expression in Early Gastric Cancer
Authors
Andrea Rodrigues Gonçalves
Antonio Jose Vasconcellos Carneiro
Ivanir Martins
Paulo Antonio Silvestre de Faria
Maria Aparecida Ferreira
Eduardo Linhares Riello de Mello
Homero Soares Fogaça
Celeste Carvalho Siqueira Elia
Heitor Siffert Pereira de Souza
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9333-z

Other articles of this Issue 2/2011

Pathology & Oncology Research 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine